EGFR and non-small cell lung carcinoma: For example, INSIGHT2 trial reported that tepotinib plus osimertinib showed promising activity and acceptable safety in EGFR-mutated NSCLC with MET amplification as a mechanism of resistance to first-line osimertinib, suggesting a potential chemotherapy-sparing oral targeted therapy option for these patients (Wu et al., 2024).